Results 121 to 130 of about 13,099 (221)

Immunotherapy in Chronic Myeloid Leukemia

, 2006
Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data generated by monitoring several thousands of patients worldwide suggest that although imatinib is highly active against the differentiated mass of CML ...
LAURIA F., BOCCHIA M.
core   +1 more source

Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.

Haematologica, 2000
Although bcr-abl polymerase chain reaction (PCR) positivity after bone marrow transplantation (BMT) for chronic myelogenous leukemia (CML) is significantly related to relapse, the predictive value of the assay is not very high and therefore most investigators consider that qualitative RT-PCR data alone are too imprecise to enable clinical decisions to ...
J, Román, J, Serrano, A, Jiménez, J A, Castillejo, M L, Reina, M G, González, M C, Rodríguez, I, García, J, Sánchez, J, Maldonado, A, Torres   +10 more
openaire   +1 more source

Novel naphthoquinone-coumarin hybrids as inhibitors of BCR-ABL-STAT5 signaling pathway in chronic myelogenous leukemia

, 2018
NPQ and coumarin represent promising scaffolds in medicinal chemistry for finding novel inhibitors of carcinogenic pathways. This is exemplified by the discovery of NPQ-coumarin hybrids as inhibitors of topoisomerase II [1]. BCR-ABL-STAT5 is an oncogenic
Martín Rodríguez, Patricia, Guerra Rodríguez, Miguel A., Díaz-Chico, J. C., Hueso-Falcón, I., Aranda Tavio, Haidee, Quintana, José, Estevez, F., Fernández Pérez, Leandro Fco, Guerra, B., Díaz Chico, Juan Carlos, Amesty, A., Estévez-Braun, A.   +11 more
core   +1 more source

p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells

, 2011
Chronic myelogenous leukemia (CML) is characterized by the expression of BCR-ABL tyrosine kinase, which results in increased cell proliferation and inhibition of apoptosis. In this study, we show that BCR-ABL-positive CML cell lines treated with imatinib
Bencivenga D, Danise P, Usala E, DELLA RAGIONE, Fulvio, Caldarelli I, Ronzoni L, OLIVA, Adriana, PERROTTA, Silverio, Cucciolla V, BORRIELLO, Adriana   +9 more
core   +1 more source

Apoptosis and mitotic slippage following drug intervention in leukaemia cells

, 2011
PhDThe response of leukaemia cells to therapeutic agents includes cell cycle arrest and apoptosis. The former response is useful in retarding disease progression, but induction of the latter is essential for disease eradication.
Omar, Najood Amer
core  

Alternative splicing of BCR/ABL in chronic myelogenous leukemia

, 1999
grantor: University of TorontoThe hallmark of chronic myelogenous leukemia (CML) is the presence of the Philadelphia chromosome and its resultant fusion message, 'BCR-ABL ', and fusion protein, p210.
Lichty, Brian Dennis
core  

Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro [PDF]

, 2012
Lyons, John, Holyoake, Tessa L., Jorgensen, Heather, Shah, Mohsin, Gallipoli, Paolo   +4 more
core   +1 more source

Gene Mutation Profile in Chronic Myelogenous Leukemia BCR-ABL. Positive Chronic Phase Patients Which not Response to lmatinib Treatment in Dr. Soetomo Teaching Hospital Surabaya lndonesia

, 2014
To determine patterns of gene mutations in BCR-ABL tyrosine kinase in chronic myelogenous leukemia BCR-ABL positive chronic phase are not complete molecular response to lmatinib treatment methods: Gene Mutation Analysis has been done in sixteen chronic
Ugroseno Yudho Bintoro, Siprianus
core  

Concurrent Chronic Myeloid Leukemia and Metastatic Renal Cell Carcinoma in a 61-year-old Female: Successful Treatment with Low-Dose Immunotherapy and Combination Targeted Therapy. [PDF]

J Kidney Cancer VHL
Gupta A, Zaidi S, Ravishankar U, Kalra S, Taneja S, Baweja P.   +5 more
europepmc   +1 more source

Multimodal gene and targeted drug therapy for chronic myelogenous leukemia using BIM/MCL-1 chimeric nanoparticle: computational target analysis and therapeutic validation. [PDF]

Nano Converg
Lugin ML, Lei W, Lee RT, Chung JY, Katritsis NM, Hwang W, Fleischman AG, Han N, Kwon YJ.   +8 more
europepmc   +1 more source